Renaissance Technologies’s Akero Therapeutics AKRO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-118,100
| Closed | -$5.61M | – | 3206 |
|
|
2025
Q3 | $5.61M | Buy |
118,100
+90,100
| +322% | +$4.36M | 0.01% | 1418 |
|
|
2025
Q2 | $1.49M | Sell |
28,000
-171,000
| -86% | -$7.77M | ﹤0.01% | 2291 |
|
|
2025
Q1 | $8.06M | Buy |
199,000
+178,200
| +857% | +$7.55M | 0.01% | 1126 |
|
|
2024
Q4 | $579K | Buy |
+20,800
| New | +$630K | ﹤0.01% | 2776 |
|
|
2024
Q3 | – | Sell |
-24,100
| Closed | -$565K | – | 3503 |
|
|
2024
Q2 | $565K | Buy |
+24,100
| New | +$515K | ﹤0.01% | 2639 |
|
|
2023
Q2 | – | Sell |
-168,900
| Closed | -$6.46M | – | 3883 |
|
|
2023
Q1 | $6.46M | Buy |
168,900
+101,300
| +150% | +$4.52M | 0.01% | 1335 |
|
|
2022
Q4 | $3.7M | Buy |
67,600
+3,500
| +5% | +$150K | 0.01% | 1692 |
|
|
2022
Q3 | $2.18M | Sell |
64,100
-57,700
| -47% | -$883K | ﹤0.01% | 1955 |
|
|
2022
Q2 | $1.15M | Buy |
121,800
+68,700
| +129% | +$716K | ﹤0.01% | 2614 |
|
|
2022
Q1 | $753K | Buy |
+53,100
| New | +$930K | ﹤0.01% | 2912 |
|
|
2021
Q1 | – | Sell |
-149,900
| Closed | -$3.87M | – | 3279 |
|
|
2020
Q4 | $3.87M | Buy |
149,900
+113,700
| +314% | +$3.16M | ﹤0.01% | 1746 |
|
|
2020
Q3 | $1.11M | Buy |
36,200
+1,716
| +5% | +$60K | ﹤0.01% | 2460 |
|
|
2020
Q2 | $859K | Buy |
+34,484
| New | +$788K | ﹤0.01% | 2619 |
|
Other funds holding AKRO
Renaissance Technologies's AKRO Position: Q4 2025 in Review
Renaissance Technologies sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 118,100 shares — an estimated $5.61M sold.
Renaissance Technologies first reported a position in AKRO in Q2 2020 and held it in 13 quarters. The position peaked at $8.06M in Q1 2025. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.
- Renaissance Technologies reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
- Renaissance Technologies sold 118,100 Akero Therapeutics shares in Q4 2025, an estimated $5.61M.
- Renaissance Technologies first reported a position in Akero Therapeutics in Q2 2020 and held it in 13 quarters.
- Renaissance Technologies's Akero Therapeutics position peaked at $8.06M in Q1 2025.
- 2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.
Based on Renaissance Technologies's 13F filing for Q4 2025, filed 12 Feb 2026.